Linked Life Data

17001625

Source:http://linkedlifedata.com/resource/pubmed/id/17001625

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2006-10-2
pubmed:abstractText
Insertional mutagenesis resulting in a leukaemia-like lymphoproliferative disease, as observed in the X-SCID (severe combined immunodeficiency) clinical trial using a gamma-retroviral vector that transferred a functional copy of the defective gene into hematopoietic precursor cells of affected children, sparked a debate about a ban on conventional gamma-retroviral vectors. This commentary summarizes the relevant data on this topic and concludes that there is no preclinical or clinical evidence as yet that SIN vectors, which self-inactivate the retroviral long terminal repeats (LTRs), will indeed show an improved safety profile. Conventional murine leukaemia virus (MLV) vectors can thus be used further in clinical gene therapy trials but require a thorough case-by-case risk-benefit analysis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1099-498X
pubmed:author
pubmed:copyrightInfo
Copyright (c) 2006 John Wiley & Sons, Ltd.
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1274-6
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Is it going to be SIN?: a European Society of Gene Therapy commentary. Phasing-out the clinical use of non self-inactivating murine leukemia virus vectors: initiative on hold.
pubmed:affiliation
Paul-Ehrlich-Institut, Division of Medical Biotechnology, 63225 Langen, Germany.
pubmed:publicationType
Journal Article, Evaluation Studies